(GH) Guardant Health - Overview
Stock: Blood Tests, Tissue Tests, Liquid Biopsy, Companion Diagnostics, Data Platform
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 65.5% |
| Relative Tail Risk | -12.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.51 |
| Alpha | 98.13 |
| Character TTM | |
|---|---|
| Beta | 1.019 |
| Beta Downside | 1.170 |
| Drawdowns 3y | |
|---|---|
| Max DD | 59.79% |
| CAGR/Max DD | 0.91 |
Description: GH Guardant Health January 08, 2026
Guardant Health, Inc. (NASDAQ:GH) is a precision-oncology firm that commercializes a suite of liquid-biopsy and tissue-based genomic tests-including Guardant360, Guardant360 CDx, GuardantINFINITY, and GuardantConnect-to identify actionable mutations and support clinical trial enrollment for cancer patients worldwide.
Key recent metrics: FY 2023 revenue reached approximately $1.1 billion, up ~30 % YoY, driven largely by Guardant360 CDx adoption; the company reported a cash runway of roughly 18 months after a $300 million financing round in Q3 2024; and its partnership with Roche to co-develop companion diagnostics for KRAS-mutated colorectal cancer is expected to expand market penetration.
Sector dynamics that materially affect Guardant: the global liquid-biopsy market is projected to grow at a CAGR of 23 % through 2030, buoyed by increasing payer reimbursement for non-invasive testing and a shift toward earlier-stage cancer detection; meanwhile, regulatory trends-such as the FDA’s recent guidance on next-generation sequencing companion diagnostics-create both compliance costs and entry barriers that favor incumbents with cleared assays.
For a deeper, data-driven assessment of Guardant’s valuation relative to these trends, you may find the ValueRay analysis worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income: -398.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.21 > 0.02 and ΔFCF/TA -2.71 > 1.0 |
| NWC/Revenue: 65.59% < 20% (prev 148.7%; Δ -83.11% < -1%) |
| CFO/TA -0.17 > 3% & CFO -222.9m > Net Income -398.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.50 > 1.5 & < 3 |
| Outstanding Shares: last quarter (125.3m) vs 12m ago 1.83% < -2% |
| Gross Margin: 63.76% > 18% (prev 0.81%; Δ 6295 % > 0.5%) |
| Asset Turnover: 64.11% > 50% (prev 44.99%; Δ 19.13% > 0%) |
| Interest Coverage Ratio: -117.3 > 6 (EBITDA TTM -354.1m / Interest Expense TTM 3.36m) |
Altman Z'' -8.01
| A: 0.46 (Total Current Assets 828.9m - Total Current Liabilities 236.9m) / Total Assets 1.28b |
| B: -2.24 (Retained Earnings -2.87b / Total Assets 1.28b) |
| C: -0.28 (EBIT TTM -394.2m / Avg Total Assets 1.41b) |
| D: -1.76 (Book Value of Equity -2.87b / Total Liabilities 1.63b) |
| Altman-Z'' Score: -8.01 = D |
Beneish M -0.57
| DSRI: 1.00 (Receivables 115.6m/88.5m, Revenue 902.6m/692.3m) |
| GMI: 1.27 (GM 63.76% / 81.07%) |
| AQI: 4.60 (AQ_t 0.13 / AQ_t-1 0.03) |
| SGI: 1.30 (Revenue 902.6m / 692.3m) |
| TATA: -0.14 (NI -398.8m - CFO -222.9m) / TA 1.28b) |
| Beneish M-Score: -0.57 (Cap -4..+1) = D |
What is the price of GH shares?
Over the past week, the price has changed by -10.69%, over one month by -9.33%, over three months by +5.82% and over the past year by +120.98%.
Is GH a buy, sell or hold?
- StrongBuy: 15
- Buy: 6
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the GH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 125.2 | 23% |
| Analysts Target Price | 125.2 | 23% |
| ValueRay Target Price | 98.8 | -3% |
GH Fundamental Data Overview February 07, 2026
P/B = 55.6696
Revenue TTM = 902.6m USD
EBIT TTM = -394.2m USD
EBITDA TTM = -354.1m USD
Long Term Debt = 1.11b USD (from longTermDebt, last quarter)
Short Term Debt = 26.4m USD (from shortTermDebt, last quarter)
Debt = 1.33b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 746.4m USD (from netDebt column, last quarter)
Enterprise Value = 13.52b USD (12.77b + Debt 1.33b - CCE 580.0m)
Interest Coverage Ratio = -117.3 (Ebit TTM -394.2m / Interest Expense TTM 3.36m)
EV/FCF = -51.56x (Enterprise Value 13.52b / FCF TTM -262.2m)
FCF Yield = -1.94% (FCF TTM -262.2m / Enterprise Value 13.52b)
FCF Margin = -29.05% (FCF TTM -262.2m / Revenue TTM 902.6m)
Net Margin = -44.18% (Net Income TTM -398.8m / Revenue TTM 902.6m)
Gross Margin = 63.76% ((Revenue TTM 902.6m - Cost of Revenue TTM 327.1m) / Revenue TTM)
Gross Margin QoQ = 64.71% (prev 65.01%)
Tobins Q-Ratio = 10.59 (Enterprise Value 13.52b / Total Assets 1.28b)
Interest Expense / Debt = 0.07% (Interest Expense 943.0k / Debt 1.33b)
Taxrate = 21.0% (US default 21%)
NOPAT = -311.5m (EBIT -394.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.50 (Total Current Assets 828.9m / Total Current Liabilities 236.9m)
Debt / Equity = -3.74 (negative equity) (Debt 1.33b / totalStockholderEquity, last quarter -354.5m)
Debt / EBITDA = -2.11 (negative EBITDA) (Net Debt 746.4m / EBITDA -354.1m)
Debt / FCF = -2.85 (negative FCF - burning cash) (Net Debt 746.4m / FCF TTM -262.2m)
Total Stockholder Equity = -262.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -28.33% (Net Income -398.8m / Total Assets 1.28b)
RoE = 151.9% (negative equity) (Net Income TTM -398.8m / Total Stockholder Equity -262.6m)
RoCE = -46.27% (EBIT -394.2m / Capital Employed (Equity -262.6m + L.T.Debt 1.11b))
RoIC = -36.23% (negative operating profit) (NOPAT -311.5m / Invested Capital 859.7m)
WACC = 8.77% (E(12.77b)/V(14.10b) * Re(9.67%) + D(1.33b)/V(14.10b) * Rd(0.07%) * (1-Tc(0.21)))
Discount Rate = 9.67% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.83%
Fair Price DCF = unknown (Cash Flow -262.2m)
EPS Correlation: 88.82 | EPS CAGR: 55.64% | SUE: 3.35 | # QB: 4
Revenue Correlation: 98.90 | Revenue CAGR: 27.03% | SUE: 3.39 | # QB: 6
EPS next Quarter (2026-03-31): EPS=-0.44 | Chg30d=-0.001 | Revisions Net=+0 | Analysts=11
EPS next Year (2026-12-31): EPS=-1.44 | Chg30d=+0.001 | Revisions Net=-1 | Growth EPS=+20.3% | Growth Revenue=+27.7%